Protocol - Eye Drop Use
Description
A series of five questions to assess the participants current use of drops for glaucoma, artificial tears or prescription medication for dry eyes, and steroid eye drops.
Specific Instructions
None
Availability
Protocol
Administration Instructions:
Question 3: There are many manifestations of "dry eye" besides the symptoms in the question, including excess tearing. Most people will be familiar with this condition. They need not have been told by an eye doctor they have this condition. Emphasize "for the past 3 months or longer" when you ask this question. If the participant has occasional episodes of dry eye, it should on average be a complaint at least 4 out of 7 days for the past 3 months or longer. Emphasize "not related to allergy" when using the probe for this question.
Question 4: There are a number of over-the-counter artificial tears which are used for this condition. Visine, taken for allergies, does not qualify as an artificial tear unless specifically prescribed for dry eye. Drops taken for contact lens do not qualify as artificial tears for dry eye. Note that the question requires current (4 out of 7 days) use for 3 months or longer.
1. Is the participant currently taking drops for glaucoma?
0[ ]no
2[ ]yes
8[ ]uncertain
2. What is the name of the glaucoma drops you are using?
2865[ ]Alphagan?
1152[ ]Betagen?
1156[ ]Betopic
2770[ ]CoSopt?
2014[ ]Pilocar?
2298[ ]Timolol
2299[ ]Timoptic?
2437[ ]Xalatan?
[ ] Other _________________
8001[ ]Unknown
3. For the past 3 months or longer, have you had dry eyes? (foreign body sensation with itching and burning, sandy feeling, NOT related to allergy)
0[ ]no
2[ ]OD
3[ ]OS
4[ ]OU
5[ ]?eye
8[ ]DK
4. Do you currently use artificial tears or prescription medication for dry eyes regularly for 3 months or longer?
0[ ]no
2[ ]yes
8[ ]DK
5. Are you currently using steroid eye drops?
0[ ]no
2[ ]yes
8[ ]DK
Alphagan? and Betagen? are a registered trademarks of Allergan, Inc,; CoSopt? and Timoptic? are registered trademarks of Merck & Co., Inc.; Pilocar? is a registered trademark of Novartis Corporation; Xalatan? is a registered trademark of Pfizer Health AB.
Personnel and Training Required
The interviewer must be trained to conduct personal interviews with individuals from the general population. The interviewer must be trained and found to be competent (i.e. tested by an expert) at the completion of personal interviews*.
*There are multiple modes to administer this question (i.e., pencil and paper and computer-assisted interviews).
Equipment Needs
Either a pencil and paper or computer-assisted instrument may be used. If a computer-assisted instrument is used, computer software may be necessary to develop the instrument. The interviewer will require a laptop computer/handheld computer to administer a computer-assisted questionnaire.
Requirements
| Requirement Category | Required |
|---|---|
| Major equipment | No |
| Specialized training | No |
| Specialized requirements for biospecimen collection | No |
| Average time of greater than 15 minutes in an unaffected individual | No |
Mode of Administration
Interviewer-administered questionnaire
Lifestage
Adult
Participants
Adults aged 43 to 86 years*
* While this protocol was used in a study of adults aged 43 to 86 years, the Ocular Working Group suggests that the same methodology can be used for individuals aged 18 years or older.
Selection Rationale
The questions suggested have had wide use in long term studies of ocular diseases.
Language
Chinese, English
Standards
| Standard | Name | ID | Source |
|---|---|---|---|
| Logical Observation Identifiers Names and Codes (LOINC) | Eye drop use proto | 62687-9 | LOINC |
| caDSR Form | PhenX PX110501 - Eye Drop Use | 5972004 | caDSR Form |
Derived Variables
None
Process and Review
Not applicable.
Protocol Name from Source
Beaver Dam Eye Study
Source
National Eye Institute, University of Wisconsin, Beaver Dam Eye StudyBeaver Dam V- 20 Year Follow-Up Interview Form
Question numbers: 55-570 [GLAU-DROPS5] (question 1), 55-572 [GLAU-NAME5] (question 2), 56-092 [DRY-EYE5] (question 3), 56-094 [DRY-EYE-RX5] (question 4), and 56-114 [STEROIDROP5] (question 5).
Last revised 2/6/09
General References
Wong TY, Knudtson MD, Klein BE, Klein R, Hubbard LD. (2005). Medication use and retinal vessel diameters. Am J Ophthalmol, 139(2):373-5.
Protocol ID
110501
Variables
Export Variables| Variable Name | Variable ID | Variable Description | dbGaP Mapping | |
|---|---|---|---|---|
| PX110501_Currently_Take_Glaucoma_Drops | ||||
| PX110501010000 | Is the participant currently taking drops more | Variable Mapping | ||
| PX110501_Currently_Use_Steroid_Eye_Drops | ||||
| PX110501050000 | Are you currently using steroid eye drops? | Variable Mapping | ||
| PX110501_Dry_Eyes_Past_3_Months | ||||
| PX110501030000 | For the past 3 months or longer, have you more | Variable Mapping | ||
| PX110501_Dry_Eye_Artificial_Tears_Prescription_Medication | ||||
| PX110501040000 | Do you currently use artificial tears or more | Variable Mapping | ||
| PX110501_Glaucoma_Drops_Name | ||||
| PX110501020100 | What is the name of the glaucoma drops you more | N/A | ||
| PX110501_Glaucoma_Drops_Name_Specify | ||||
| PX110501020200 | Specify other glaucoma drops you are using. | N/A | ||
Measure Name
Eye Drop Use
Release Date
February 26, 2010
Definition
Questions to determine current and recent eye drop use
Purpose
These questions are to assess use of eye drops in general for those investigators who are interested in use of both prescription and over the counter medications. Use of specific medications may be used to augment information about the burden of specific eye conditions such as glaucoma. Also, some of the medications have systemic effects which may be of interest to an investigator.
Keywords
Ocular, Eye, Eye drops, Artificial tears, Medications, Beaver Dam Eye Study
Measure Protocols
| Protocol ID | Protocol Name |
|---|---|
| 110501 | Eye Drop Use |
Publications
There are no publications listed for this protocol.